The Purpose of This Study is to Determine the Safety, Tolerability, and Pharmacokinetics of Brexpiprazole Long-acting Injection Following a Single Administration in Healthy Subjects/Patients With Schizophrenia.

This study is testing the safety, tolerability, and blood levels of a long-acting injectable version of brexpiprazole — an antipsychotic medication — in both healthy volunteers and patients with schizophrenia. Long-acting injectables are given every few weeks instead of daily, which can improve medication adherence. **You may be eligible if (Healthy Volunteers)...** - You are between 18 and 65 years old with a BMI between 19 and 26 - You are in good general health and have no plans for pregnancy during and for 1 year after the study - You can communicate clearly with the research team **You may be eligible if (Patients with Schizophrenia)...** - You have a confirmed schizophrenia diagnosis and are currently on stable oral brexpiprazole - Your symptoms are in a stable phase **You may NOT be eligible if...** - You have significant heart, liver, kidney, or blood disorders - You are pregnant, breastfeeding, or planning pregnancy - You are allergic to brexpiprazole or similar medications Talk to your doctor to see if this trial is right for you.